TCL Archive Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial By Cancer History Project January 27, 2012
TCL Archive News Analysis by Keith Baggerly: Duke Trials Went On Despite FDA Statements By Cancer History Project January 27, 2012
TCL Archive ETP-ALL May Be Linked To Acute Myeloid Leukemia By Cancer History Project January 27, 2012
TCL Archive CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup By Cancer History Project January 27, 2012
TCL Archive BRCA1 and BRCA2 Mutations Linked To Higher Survival By Cancer History Project January 27, 2012
TCL Archive Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease By Cancer History Project January 27, 2012
TCL Archive Chromosomal Abnormalities Predict Long Median Survival By Cancer History Project January 27, 2012
TCL Archive Analysis Shows No Mortality Benefit From Regular PSA Screening By Cancer History Project January 27, 2012
People Larry Einhorn, pioneer of platinum-based chemotherapy, discusses 50 years of cancer treatment innovation By Cancer History Project
